

Jubilant Life Sciences International Pte. Limited
Balance Sheet as at 31 March 2023

		USD	INR (In Thousands)	USD	INR (In Thousands)
	Notes	As at 31 March 2023		As at 31 March 2022	
ASSETS					
Non-current assets					
Financial assets					
Investments	1	200,000	16,434	200,000	15,159
Loans and advances	2	19,203,761	1,577,973	19,203,693	1,455,496
Income tax asset (net)	3	-	-	4,964	376
Total non-current assets		19,403,761	1,594,407	19,408,657	1,471,031
Current assets					
Financial assets					
Cash and cash equivalents	4	1,639,635	134,729	669,623	50,752
Other financial assets	5	137,514	11,300	417,278	31,627
Total current assets		1,777,149	146,029	1,086,901	82,379
Total assets		21,180,910	1,740,436	20,495,558	1,553,410
EQUITY AND LIABILITIES					
Equity					
Equity share capital	6	437,503	19,990	437,503	19,990
Other equity		20,730,112	1,719,353	19,991,624	1,528,384
Total equity		21,167,615	1,739,343	20,429,127	1,548,374
LIABILITIES					
Non-current liabilities					
Deferred tax liabilities (net)		-	-	44,124	3,344
Total non-current liabilities		-	-	44,124	3,344
Current liabilities					
Financial liabilities					
Trade payables	7	7,884	648	16,808	1,275
Current tax liabilities	8	5,411	445	5,499	417
Total current liabilities		13,295	1,093	22,307	1,692
Total liabilities		13,295	1,093	66,431	5,036
Total equity and liabilities		21,180,910	1,740,436	20,495,558	1,553,410

SS Hariharasubramaniam
Sr. Director – Accounts
Place: Noida
Date: 16 May 2023

Jubilant Life Sciences International Pte. Limited
Statement of Profit and Loss for the year ended 31 March 2023

Particulars	Notes	USD		INR (In Thousands)	
		For the year ended 31 March 2023	For the year ended 31 March 2022	For the year ended 31 March 2023	For the year ended 31 March 2022
Other income	9	768,000	61,678	329,178	24,668
Total income		768,000	61,678	329,178	24,668
Expenses					
Other expenses	10	14,613	1,170	28,493	2,128
Total expenses		14,613	1,170	28,493	2,128
Profit before tax		753,387	60,508	300,685	22,540
Tax expense					
- Current tax		59,023	4,851	3,907	291
- Deferred tax		(44,124)	(3,406)	43,649	3,275
Total tax expense		14,899	1,445	47,556	3,566
Profit after tax		738,488	59,063	253,129	18,974
Other comprehensive income					
Equity Instrument through Other comprehensive income		-	-	12,093,138	896,080
<i>Items that will not be reclassified to profit or loss</i>					
Exchange differences on translation of foreign operations		-	131,906	-	41,632
Other comprehensive income/(loss) for the year, net of tax		-	131,906	12,093,138	937,712
Total comprehensive income/(loss) for the year		738,488	190,969	12,346,267	956,686

SS Hariharasubramaniam
Sr. Director – Accounts
Place: Noida
Date: 16 May 2023

Jubilant Life Sciences International Pte. Limited
Statement of changes in Equity for the year ended 31st March 2023

A. Equity share capital

	USD	INR (In Thousands)
Balance as at 1 April 2021	437,503	19,990
Changes in equity share capital during the year	-	-
Balance as at 31 March 2022	437,503	19,990
Changes in equity share capital during	-	-
Balance as at 31 March 2023	437,503	19,990

B. Other equity

	Retained earnings		Equity Instrument through OCI		Reserves and surplus			Total	
					Capital Reserve		Exchange differences on translation of foreign operations		
	USD	INR (In Thousands)	USD	INR (In Thousands)	USD	INR (In Thousands)		USD	INR (In Thousands)
Balance as at 1 April 2021	1,145,833	77,993	(558,146)	(54,414)	7,057,670	473,429	74,690	7,645,357	571,698
Profit for the year	253,129	18,974	-	-	-	-	-	253,129	18,974
Addition during the year- Equity OCI	-	-	12,093,138	896,080	-	-	-	12,093,138	896,080
Exchange differences on translation of foreign operations	-	-	-	-	-	-	41,632	-	41,632
Balance as at 31 March 2022	1,398,962	96,967	11,534,992	841,666	7,057,670	473,429	116,322	19,991,624	1,528,384
Balance as at 1 April 2022	1,398,962	96,967	11,534,992	841,666	7,057,670	473,429	116,322	19,991,624	1,528,384
Profit for the year	738,488	59,063	-	-	-	-	-	738,488	59,063
Addition during the year- Equity OCI	-	-	-	-	-	-	-	-	-
Exchange differences on translation of foreign operations	-	-	-	-	-	-	131,906	-	131,906
Balance as at 31 March 2023	2,137,450	156,030	11,534,992	841,666	7,057,670	473,429	248,228	20,730,112	1,719,353

SS Hariharasubramaniam
Sr. Director – Accounts
Place: Noida
Date: 16 May 2023

Jubilant Life Sciences International Pte. Limited
Statement of Cash Flows for the year ended 31 March 2023

Particulars	USD	INR (In Thousands)	USD	INR (In Thousands)
	For the year ended 31 March 2023		For the year ended 31 March 2022	
A. Cash flow from operating activities				
Net profit before tax	753,387	60,508	300,685	22,540
Adjustments :				
Interest Income	(768,000)	(61,678)	(329,178)	(24,668)
Operating cash flow before working capital changes	(14,613)	(1,170)	(28,493)	(2,128)
(Increase)/ decrease in other current assets and loan and advances	(68)	(6)	25	2
Decrease in trade payables and current liabilities	(8,924)	(716)	(11,698)	(871)
Cash used in operations	(23,605)	(1,892)	(40,166)	(2,997)
Income tax paid (net of refund)	(54,147)	(4,346)	(2,788)	(208)
Net cash (used in)/ generated from operating activities	(77,752)	(6,238)	(42,954)	(3,205)
B. Cash flow from investing activities				
Interest Received	1,047,764	84,099	54,000	4,022
Sale of investment	-	-	18,405,747	1,370,816
Loan given to related parties	-	-	(18,000,000)	(1,340,597)
Net cash used in investing activities	1,047,764	84,099	459,747	34,241
C. Effect of exchange rate changes				
	-	6,116	-	1,232
Net increase in cash and cash equivalents (A+B+C)	970,012	83,977	416,793	32,268
Add: cash and cash equivalents at the beginning of year	669,623	50,752	252,830	18,484
Cash and cash equivalents at the end of the year	1,639,635	134,729	669,623	50,752

SS Hariharasubramaniam

Sr. Director – Accounts

Place: Noida

Date: 16 May 2023

Jubilant Life Sciences International Pte. Limited
Notes to the financial statements for the year ended 31 March 2023

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31 March 2023		As at 31 March 2022	
Note 1. Non-current investments				
Investment in subsidiaries				
Investment in Jubilant Life Sciences (Shanghai) Limited 200,000 (31 March 2022:200,000 equity share of USD 1 each)	200,000	16,434	200,000	15,159
	200,000	16,434	200,000	15,159
Note 2. Long term loan and advances				
Security deposits	3,761	309	3,693	280
Loans to related parties	19,200,000	1,577,664	19,200,000	1,455,216
	19,203,761	1,577,973	19,203,693	1,455,496
Note 3. Income tax assets(net)				
Advance payment of income tax/ wealth tax (including TDS)	-	-	4,964	376
	-	-	4,964	376
Note 4. Cash and cash equivalent				
Balances with banks:				
- On current accounts	1,639,635	134,729	669,623	50,752
	1,639,635	134,729	669,623	50,752
Note 5. Other financial assets				
Advance and interest recoverable-related party	137,514	11,300	417,278	31,627
	137,514	11,300	417,278	31,627

Jubilant Life Sciences International Pte. Limited
Statement of changes in Equity for the year ended 31st March 2023

Note 6: Equity share capital

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31 March 2023		As at 31 March 2022	
Issued, subscribed and paid up share capital				
437,503 (31 March 2022: 437,503 Equity shares with no par value)	437,503	19,990	437,503	19,990
	437,503	19,990	437,503	19,990

1). Movement in Equity share capital

	No. of shares	USD	INR (In Thousands)
Balance as at 1 April 2021	437,503	437,503	19,990
Changes in equity share capital during the year	-	-	-
Balance as at 31 March 2022	437,503	437,503	19,990
Changes in equity share capital during the year	-	-	-
Balance as at 31 March 2023	437,503	437,503	19,990

2) Terms and rights attached to equity shares

The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.

3) The details of shareholders holding more than 5% shares in the company

Name of the Shareholder	As at 31 March 2023		As at 31 March 2022	
	No. of shares	% holding in the class	No. of shares	% holding in the class
Jubilant Ingrevia Limited	437,503	100%	437,503	100%

Jubilant Life Sciences International Pte. Limited
Notes to the financial statements for the year ended 31 March 2023

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31 March 2023		As at 31 March 2022	
Note 7. Trade payables				
Trade payables	7,884	648	16,808	1,275
	7,884	648	16,808	1,275
Note 8. Current tax liabilities				
Provision for income tax	5,411	445	5,499	417
	5,411	445	5,499	417
Note 9. Other income				
Interest Income	768,000	61,678	329,178	24,668
	768,000	61,678	329,178	24,668
Note 10. Other expenses				
Auditors remuneration	7,065	568	6,357	473
Legal, professional and consultancy charges	6,862	548	21,147	1,581
Bank charges	754	60	964	72
Foreign exchange (gain) / loss	(68)	(6)	25	2
	14,613	1,170	28,493	2,128